Long‑term disease free survival of gastric mixed adenoneuroendocrine carcinoma treated with multimodality therapy: A case report

Yang,Guangjian; Li,Dan; Zheng,Fangchao; Yang,Lin

doi:10.3892/mco.2018.1594

Long‑term disease free survival of gastric mixed adenoneuroendocrine carcinoma treated with multimodality therapy: A case report

Authors:
- Guangjian Yang
- Dan Li
- Fangchao Zheng
- Lin Yang
View Affiliations

Affiliations: Medical Department of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China, Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China, Department of Oncology, Shouguang Hospital of Traditional Chinese Medicine, Weifang 262700, P.R. China
Published online on: March 26, 2018 https://doi.org/10.3892/mco.2018.1594
Pages: 653-656

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric mixed adenoneuroendocrine carcinoma, a rare malignant type of stomach tumor, is composed of components of adenocarcinoma and neuroendocrine tumor. This type of neoplasm usually has a poor prognosis since both components are malignant. A 65‑year‑old male presented with norexia, epigastric distention, abdominal and lumbar pain. Contrast computed tomography scan of the abdomen verified multiple lesions merged into a large mass. Histolopathological examination of the specimen from digestive endoscopy was verified to be gastric mixed adenoneuroendocrine carcinoma. The patient received a multimodality treatment of chemotherapy, surgical resection with radiotherapy and still remains alive with no evidence of metastasis or recurrence for over 5 years. The authors suggest that multimodality therapy may be beneficial and necessary to effictively treat mixed adenoneuroendocrine carcinoma.

View Figures

View References

1	Kitajima T, Kaida S, Lee S, Haruta S, Shinohara H, Ueno M, Suyama K, Oota Y, Fujii T and Udagawa H: Mixed adeno(neuro)endocrine carcinoma arising from the ectopic gastric mucosa of the upper thoracic esophagus. World J Surg Oncol. 11:2182013. View Article : Google Scholar : PubMed/NCBI
2	Gurzu S, Kadar Z, Bara T, Bara T Jr, Tamasi A, Azamfirei L and Jung I: Mixed adenoneuroendocrine carcinoma of gastrointestinal tract: Report of two cases. World J Gastroenterol. 21:1329–1333. 2015. View Article : Google Scholar : PubMed/NCBI
3	Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A and Ramage JK: Review article: The investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 39:1071–1084. 2014. View Article : Google Scholar : PubMed/NCBI
4	Park JY, Ryu MH, Park YS, Park HJ, Ryoo BY, Kim MG, Yook JH, Kim BS and Kang YK: Prognostic significance of neuroendocrine components in gastric carcinomas. Eur J Cancer. 50:2802–2809. 2014. View Article : Google Scholar : PubMed/NCBI
5	Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jäntti C, et al: Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 53:1284–1297. 2014. View Article : Google Scholar : PubMed/NCBI
6	Norlén O, Stålberg P, Öberg K, Eriksson J, Hedberg J, Hessman O, Janson ET, Hellman P and Åkerström G: Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 36:1419–1431. 2012. View Article : Google Scholar : PubMed/NCBI
7	Richards D, Davis D, Yan P and Guha S: Unusual case of small cell gastric carcinoma: Case report and literature review. Dig Dis Sci. 56:951–957. 2011. View Article : Google Scholar : PubMed/NCBI
8	Moertel CG, Kvols LK, O'Connell MJ and Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 68:227–232. 1991. View Article : Google Scholar : PubMed/NCBI
9	Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 24:2038–2043. 2006. View Article : Google Scholar : PubMed/NCBI
10	Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA and Kvols LK: North American Neuroendocrine Tumor Society (NANETS): The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 39:799–800. 2010. View Article : Google Scholar : PubMed/NCBI
11	Brenner B, Tang LH, Shia J, Klimstra DS and Kelsen DP: Small cell carcinomas of the gastrointestinal tract: Clinicopathological features and treatment approach. Semin Oncol. 34:43–50. 2007. View Article : Google Scholar : PubMed/NCBI